Your browser doesn't support javascript.
loading
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
Taylor, Graham S; Jia, Hui; Harrington, Kevin; Lee, Lip Wai; Turner, James; Ladell, Kristin; Price, David A; Tanday, Manjit; Matthews, Jen; Roberts, Claudia; Edwards, Ceri; McGuigan, Lesley; Hartley, Andrew; Wilson, Steve; Hui, Edwin P; Chan, Anthony T C; Rickinson, Alan B; Steven, Neil M.
Affiliation
  • Taylor GS; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Jia H; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Harrington K; Division of Cancer Biology, The Institute of Cancer Research/The Royal Marsden Hospital, London, United Kingdom.
  • Lee LW; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Turner J; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Ladell K; Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Price DA; Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Tanday M; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Matthews J; Division of Cancer Biology, The Institute of Cancer Research/The Royal Marsden Hospital, London, United Kingdom.
  • Roberts C; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Edwards C; Cancer Research UK Drug Development Office, London, United Kingdom.
  • McGuigan L; Cancer Research UK Drug Development Office, London, United Kingdom.
  • Hartley A; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Wilson S; Health Protection Agency, West Midlands Public Health Laboratory, Heart of England Foundation Trust, Bordesley Green East, Birmingham, United Kingdom.
  • Hui EP; Partner State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Hong Kong Cancer Institute and Li Ka Shing Institute for Health Sciences, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Chan AT; Partner State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Hong Kong Cancer Institute and Li Ka Shing Institute for Health Sciences, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Rickinson AB; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Steven NM; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom. n.m.steven@bham.ac.uk.
Clin Cancer Res ; 20(19): 5009-22, 2014 Oct 01.
Article in En | MEDLINE | ID: mdl-25124688

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccinia virus / Herpesvirus 4, Human / Cancer Vaccines / Epstein-Barr Virus Nuclear Antigens / Epstein-Barr Virus Infections / Neoplasms Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: United kingdom Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccinia virus / Herpesvirus 4, Human / Cancer Vaccines / Epstein-Barr Virus Nuclear Antigens / Epstein-Barr Virus Infections / Neoplasms Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: United kingdom Country of publication: United States